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Venous endothelial cells are molecularly and functionally distinct from their arterial coun-
terparts. Although veins are often considered the default endothelial state, genetic manip-
ulations can modulate both acquisition and loss of venous fate, suggesting that venous
identity is the result of active transcriptional regulation. However, little is known about
this process. Here we show that BMP signalling controls venous identity via the ALK3/
BMPR1A receptor and SMAD1/SMAD5. Perturbations to TGF-β and BMP signalling in
mice and zebraﬁsh result in aberrant vein formation and loss of expression of the venous-
speciﬁc gene Ephb4, with no effect on arterial identity. Analysis of a venous endothelium-
speciﬁc enhancer for Ephb4 shows enriched binding of SMAD1/5 and a requirement for
SMAD binding motifs. Further, our results demonstrate that BMP/SMAD-mediated Ephb4
expression requires the venous-enriched BMP type I receptor ALK3/BMPR1A. Together,
our analysis demonstrates a requirement for BMP signalling in the establishment of Ephb4
expression and the venous vasculature.
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Arteriovenous differentiation begins prior to the onset ofblood ﬂow, indicating an important role for genetic fatedetermination1. Mammalian arterial–venous fate is
acquired in a stepwise manner: arterial identity is established ﬁrst,
while the initial venous structures express both arterial and
venous markers prior to embryonic day (E) 9.0, when full venous
differentiation occurs concurrent with the expression of Eph
receptor B4 (Ephb4)2. Ephb4, encoding a transmembrane tyrosine
kinase, is highly expressed in deﬁnitive venous endothelium but
is not found in arterial endothelium. Consequently, it is often
treated as the deﬁnitive venous endothelial identity marker,
although some expression is also detected in capillaries and
in lymphatic valves3,4. Loss of Ephb4 expression results in
embryonic lethality by E10.5, with signiﬁcant defects in the for-
mation of the cardinal vein while the dorsal aorta is relatively
unaffected5.
It has been hypothesized that endothelial cells (ECs) are venous
by default while arterial identity is acquired; however, growing
evidence suggests that venous EC identity is dependent upon
dynamic gene regulation. For example, the phosphoinositide-3
kinase-AKT pathway downstream of vascular endothelial growth
factor (VEGF-A) actively promotes venous differentiation
through inhibition of extracellular signal–regulated kinase/mito-
gen-activated protein kinase (ERK/MAPK)6, whereas the venous-
speciﬁc orphan nuclear receptor Coup-TFII (Nr2f2) actively
represses arterial gene expression7. However, relatively little is
known about the regulatory mechanisms that control venous
differentiation: no venous speciﬁc enhancers or promoters have
been described in the literature, and it is unclear whether venous
gene expression is actively stimulated in veins or repressed
in arteries.
While the roles of the Notch and VEGF-A signalling pathways
in arteriovenous differentiation have been thoroughly investi-
gated, the involvement of other vascular signalling networks in
this process is less well understood. In particular, the precise role
played by transforming growth factor (TGF)-β signalling in
arteriovenous differentiation has been challenging to determine.
The TGF-β superfamily of pleiotropic cytokines, including three
TGF-β and multiple bone morphogenetic protein (BMP) ligands,
are widely found in blood vessels, as are their cognate type II and
type I transmembrane receptor kinases8. Ligand binding results in
the intracellular phosphorylation of the receptor-regulated
SMADs (R-SMADs), which form heteromeric complexes with
the common-mediator SMAD4 and translocate to the nucleus
where they directly bind DNA9.
Mutations in the BMP receptor ALK1(ACVRL1), SMAD4 and
the accessory type III receptor ENG are associated with the
human condition Hereditary Hemorrhagic Telangiectasia (HHT),
characterized by arteriovenous malformations and mucocuta-
neous telangiectasias10. However, although gene ablation studies
in mice support a crucial role for TGF-β and BMP signalling in
the vasculature11–16, the use of different Cre lines, confounding
effects of cardiac valve defects and inconsistent analysis of
arteriovenous differentiation in these mutants has made con-
clusive analysis of the role of these pathways in early arterial and
venous identity challenging. Furthermore, while studies in zeb-
raﬁsh demonstrate a role for BMP signalling through the receptor
BMPR2 in venous-speciﬁc angiogenic sprouting1,17,18, the
requirement for BMP signalling in dorsal–ventral axis speciﬁca-
tion prior to vascular speciﬁcation has thus far prevented analysis
at stages relevant to arterial or venous identity.
In this paper, we investigate arteriovenous differentiation after
EC-speciﬁc deletion of SMAD4 in both mice and ﬁsh, demon-
strating a requirement for SMAD4 in the acquisition of venous
but not arterial identity. Further, we conduct a comprehensive
analysis of the transcriptional regulation of the essential venous
identity gene Ephb4, identifying a venous endothelial-speciﬁc
enhancer containing essential SMAD-binding motifs and
binding SMAD1/5 in ECs. Analysis of SMAD1/5 chromatin
immunoprecipitation–sequencing (ChIP-seq) data ﬁnds similar
SMAD1/5-binding peaks around other venous-associated genes,
including Coup-TFII/Nr2f2. Lastly, we demonstrate that the BMP
type I receptor ALK3/BMPR1A is speciﬁcally expressed in early
venous ECs and is required for venous identity.
Results
Absence of endothelial Smad4 results in the loss of Ephb4. To
investigate the role of the canonical TGF-β and BMP pathways in
arteriovenous identity, we re-examined the consequences of loss
of the common mediator protein SMAD4 in ECs. As reported by
Lan et al.14, mouse embryos with endothelial-speciﬁc deletion of
Smad4 (Tie2:Cre;Smad4ﬂ/ﬂ, referred to here as Smad4EC/EC) die
between E9.5 and E10.5 and exhibit growth retardation and gross
vascular defects. Analyses of wild-type (WT) and mutant mouse
embryos at E10.5 suggest that early arterial identity is unper-
turbed after Smad4 deletion: the dorsal aorta could be clearly
detected by morphological analysis, arterial markers DLL4 and
NRP1 were detected in all Smad4EC/EC embryos and expression of
the arterial Dll4in3:LacZ enhancer transgene19–21 was clearly
detected in the apparent dorsal aorta in even severely growth
retarded Smad4EC/EC; Dll4in3:LacZ embryos (Fig. 1a, b and
Supplementary Fig. 1a–d).
To analyse venous formation in the absence of SMAD4, knock-
in Ephb4LacZ/+ mice5 (which express LacZ speciﬁcally in Ephb4+
venous ECs) were crossed into the Smad4EC/EC line. Strikingly,
very little Ephb4LacZ expression was detected in Smad4EC/EC
embryos by E10.5 (Fig. 1c, d and Supplementary Fig. 1e).
Transverse sections through E10.5 Smad4EC/EC;Ephb4LacZ/+
embryos conﬁrmed the lack of Ephb4LacZ expression and revealed
a morphological absence of a discernible cardinal vein (Fig. 1d), a
phenotype shared with Ephb4 null embryos5. Loss of differentiated
venous endothelium was further conﬁrmed by immunohisto-
chemical analysis of endogenous EPHB4 and COUP-TFII (a
venous-speciﬁc orphan nuclear receptor) expression relative to the
pan-endothelial CD31 marker in Smad4+/+ and Smad4EC/EC
embryos (Fig. 1e, f). The requirement to use the endothelial-
speciﬁc Tie2:Cre driver (which is not consistently expressed in
early embryo littermates, Supplementary Fig. 1f) makes it
challenging to establish from these results whether SMAD4 is
required for initiation or maintenance of Ephb4 expression: some
venous-positioned vessels were detected in some E9.5 Smad4EC/EC
embryos (Supplementary Fig. 1g), potentially reﬂecting Smad4
expression in early vessels prior to Tie2:Cre activity or indicating
that SMAD4 is not required for initial Ephb4 expression. However,
this result clearly demonstrates a requirement for SMAD4 in
Ephb4 expression as the early veins develop and differentiate and
for the proper formation of the venous vasculature.
While these results strongly support a role for the TGF-β or
BMP pathways in venous identity, these pathways have also been
implicated in other endothelial functions, including angiogenic
sprouting, smooth muscle recruitment, vascular stability and
proliferation14,15,18,22. Therefore, it is possible that the venous
phenotype seen in Smad4EC/EC embryos is secondary to a more
general vascular defect that more severely affects veins compara-
tive to the earlier fated arteries. However, Ephb4LacZ expression
was also consistently reduced in the heterozygous Smad4EC/+;
Ephb4LacZ embryos (Fig. 1c), which were normal sized and
exhibited no embryonic lethality. Similar sized (but younger)
Smad4+/+;Ephb4LacZ/+ embryos also displayed clear venous LacZ
expression (Supplementary Fig. 2a), suggesting growth retarda-
tion was unlikely to be the principle driver of reduced Ephb4LacZ.
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Additionally, induced endothelial-speciﬁc deletion of Smad4
(referred to here as indEC) after the initial vasculature was
formed (using induction of CDH5(PAC):CreERT223 at either
E9.5 or E11.5) also resulted in signiﬁcant loss of Ephb4LacZ
activity and eventual embryonic death (Fig. 2 and Supplementary
Fig. 2b–c). While some venous structures could be detected in
these mice three days after Cre induction, they exhibited defective
morphology and fewer Ephb4lacz+ cells (Fig. 2c).
To further rule out the possibility that either a general vascular
or arterial defect underlies the lack of venous identity in Smad4EC/
EC, we examined the consequences of deleting Smad4 speciﬁcally
in a subset of ECs using a Dll4in3 enhancer-driven Cre transgenic
mouse (Dll4in3:Cre). Like endogenous Dll4, the Dll4in3 enhancer
is active in arterial but not in venous ECs and at the angiogenic
front19,21. Consequently, Dll4in3:Cre is speciﬁcally active in these
cell types (Supplementary Fig. 3a). This transgene is also active
within the endocardium and valves of the heart in similar patterns
to Tie2:Cre (Supplementary Fig. 3b–c). While analysis of the
activity of the Cre reporter Rosa26R:LacZ (R26R:LacZ) in E10.5
Tie2:Cre; Smad4ﬂ/ﬂ embryos recapitulated the venous defects
reported in Figs. 1 and 2 (Fig. 3a, b), analysis of R26R:LacZ activity
in Dll4in3:Cre;Smad4ﬂ/ﬂ embryos (referred to here as Smad4ART/
ART) found no vascular defects (Fig. 3c, d). Further, the observed
frequency of Smad4ART/ART embryos corresponded to expected
Mendelian ratios until E13.5 (Fig. 3e). This further indicates
that the early venous defects seen in Smad4EC/EC embryos are not
downstream of a general vascular phenotype or from arterial-
speciﬁc defects and that SMAD4 is not required for arterial
identity and differentiation in the early embryo.
A venous endothelium-speciﬁc enhancer for the Ephb4 gene.
Our results clearly demonstrate that vascular ablation of
SMAD4 results in the loss of Ephb4 expression and venous
development. This suggests a crucial role for TGF-β or BMP
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Fig. 1 Endothelial-speciﬁc knockout of Smad4 does not affect arterial identity but results in the loss of Ephb4 expression. a, b Representative E10.5 whole-
mount images (a) and transverse sections (b) from wild-type Smad4+/+ (n= 17), heterozygous Smad4EC/+; (n= 12) and homozygous Smad4EC/EC
(n= 10) embryos all expressing the arterial Dll4in3:LacZ transgene (ﬁve litters in total). Robust transgene expression, speciﬁc to arterial endothelial cells,
was seen in all embryos regardless of Smad4 genotype. Grey scale bars are 500 μm, black scale bars are 100 μm. c, d Representative E10.5 whole-mount
images (c) and transverse sections (d) from wild-type Smad4+/+ (n= 9), heterozygous Smad4EC/+; (n= 9) and homozygous Smad4EC/EC (n= 8) embryos
also transgenic for the venous marker Ephb4LacZ (four litters total). Robust X-gal activity is detected in the veins of Smad4+/+ embryos but is reduced in
Smad4EC/+ embryos and absent in Smad4EC/EC. Red box denotes zoomed region, grey numbers on bottom right denote the number of embryos similar to
picture shown. Grey scale bars are 500 μm, black scale bars are 100 μm. Outliers are shown in Supplementary Figure 1e. e, f Expression of the venous
endothelial cell markers EPHB4 (e) and COUP-TFII (f) in transverse sections from E10.5 Smad4+/+ and Smad4EC/EC embryos. In addition to venous
endothelial cells, COUP-TFII is expressed by arterial smooth muscle cells and other mesenchymal cells (as reported by You et al.7). White scale bars are
100 μm. EC indicates Tie2:Cre-mediated deletion, +/+ indicates Cre−, EC/+ indicates Cre+,Smad4ﬂ/+ and EC/EC indicates Cre+;Smad4ﬂ/ﬂ. da = dorsal
aorta, ica = internal carotid artery, isa = intersomitic arteries, isv = intersomitic vessel, baa = branchial arch arteries, nt = neural tube, cv = cardinal vein,
cev = branches of cerebral venous plexus. See also Supplementary Figure 1
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signalling in Ephb4 expression and consequently in venous
identity. However, analysis of Smad4 mutant embryos cannot
differentiate between direct and indirect targets of the TGF-β and
BMP pathways. Therefore, to investigate whether SMAD4 (in
combination with R-SMADs) was involved in Ephb4 expression,
we investigated the transcriptional regulation of Ephb4 in the
early vasculature. Complex spatial and temporal patterns of gene
expression often involve the use of one or more gene enhancers24,
and most endothelial-speciﬁc genes are known to be primarily
regulated by distal enhancer elements25. Enhancers are cis-acting
DNA sequences enriched for transcription factor-binding sites
and are associated with regions of open chromatin with speciﬁc
histone marks (e.g. H3K4Me1 and H3K27Ac)26. Analysis of the
Ephb4 locus for sequences rich in enhancer-associated histone
modiﬁcations and DNaseI hypersensitivity sites26–28 identiﬁed
only two regions containing these marks speciﬁcally in ECs
(Fig. 4a and Supplementary Fig. 4a). We termed these putative
regulatory elements the Ephb4-2 and Ephb4-10 enhancers,
reﬂecting their distance in kb from the transcriptional start site
(TSS). Sequence analysis after ClustalW alignment of the human
and mouse sequences of Ephb4-2 and Ephb4-10 showed that
both enhancers contained a number of conserved ETS-binding
elements (EBE), which are known to be essential for endothelial
enhancer activity25 (Supplementary Fig. 4b–d). ETS transcription
factor binding at these two sites was also indicated by analysis of a
human genome-wide map of the Ets family member ERG binding
in human umbilical vein endothelial cells (HUVECs) generated
by Fish et al.29 (Supplementary Figure 4e).
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Fig. 2 Induced endothelial-speciﬁc deletion of Smad4 after E9.5 results in reduced Ephb4 expression and dysfunctional venous structures.
a–c Representative whole-mount images (a), zoomed head region images (b) and transverse sections through head and torso regions (c) from Smad4+/+
and Smad4indEC/indEC embryos also transgenic for the venous marker Ephb4LacZ. Embryos investigated three and four days after tamoxifen induction at
E9.5 and E10.5; Smad4+/+ control for E13.5 embryos is shown in Supplementary Fig 2b. Ephb4LacZ expression was greatly decreased in Smad4indEC/indEC
embryos compared to wild-type (WT) control at E12.5 (WT n= 5, null n= 4 from two litters) and near-ablated in Smad4indEC/indEC embryos by E13.5 (n= 2
from one litter). Grey scale bars are all 1000 μm, black scale bars are all 100 μm. d Schematic detailing tamoxifen regime and timing. Blue and red boxes
denote zoomed region, numbers on bottom right-hand corner of each whole-mount image denote the number of embryos similar to picture shown. indEC
indicates CDH5(PAC):Cre/ERT2-mediated deletion, +/+ indicates Cre−. cev = branches of cerebral venous plexus, ca = cerebral artery, ccv = common
cardinal vein, ao = aortal, nt = neural tube. See also Supplementary Figure 2
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To establish whether the putative Ephb4-2 and Ephb4-10
enhancers functioned in vivo, we ﬁrst cloned the mouse
sequences upstream of the E1b minimal promoter30 and the
green ﬂuorescent protein (GFP) reporter gene (Fig. 4b) and
examined their activity in transgenic zebraﬁsh. The Ephb4-10
putative enhancer did not drive GFP expression in ECs
(Supplementary Fig. 4f). The Ephb4-2 putative enhancer was
able to direct robust GFP expression in transgenic ﬁsh speciﬁcally
in the axial veins but not in the axial arteries from early venous
speciﬁcation through later stages of differentiation (Fig. 4c and
Supplementary Fig. 4f–j). To determine whether this enhancer
was also active in mice, we next cloned the same murine Ephb4-2
enhancer upstream of the hsp68 minimal promoter and LacZ
reporter gene and generated transgenic mice. As expected, the
Ephb4-2 enhancer was able to drive reporter gene activity
speciﬁcally to venous ECs during embryonic development
(Fig. 4d, e). Tg(Ephb4-2:LacZ) mouse embryos showed patterns
of LacZ expression strikingly similar to those seen in Ephb4LacZ/+
embryos (Fig. 4e), although the intensity of expression was
greater in the enhancer line, reﬂecting the multiple copies of the
Ephb4-2:LacZ transgene comparative to the single copy in
Ephb4LacZ/+ knock-in. Of note, Ephb4-2:LacZ expression exactly
correlated with the speciﬁc expression of endogenous Ephb4 in
the venous intersomitic vessels. This contrasts with the activity of
Ephb4-2:GFP in zebraﬁsh, where expression was seen in the
orthologous intersegmental arteries and veins (Fig. 4). This
discrepancy may be due to differences in the pathways driving the
formation of these vessels between mammals and ﬁsh (as the
Ephb4-2:GFP transgene contains the mouse sequence) or reﬂect
the requirement for ﬂow in the speciﬁcation of these vessels in
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Fig. 3 Deletion of Smad4 speciﬁcally in arterial endothelial cells does not affect vascular patterning or early embryonic development. a, b Representative
pan-endothelial Tie2:Cre;Smad4ﬂ/+ and Tie2:Cre;Smad4ﬂ/ﬂ whole-mount images (a) and transverse sections (b) from E10.5 embryos also transgenic for the
Cre-reporter Rosa26R:LacZ. The cardinal vein (cv) cannot be identiﬁed in the Smad4ﬂ/ﬂ embryo, although the dorsal aorta (da) can be seen in both. Grey
scale bars are 500 μm, black scale bars are 100 μm. c, d Representative arterial-speciﬁc Dll4in3:Cre;Smad4ﬂ/+ and Dll4in3:Cre;Smad4ﬂ/ﬂ whole-mount
images (c) and transverse sections (d) from E10.5 embryos also transgenic for the Cre-reporter Rosa26R:LacZ. Arterial-speciﬁc deletion of Smad4 had
no effect on vasculature development at E10.5. Grey scale bars are 500 μm, black scale bars are 100 μm. e Observed frequency of Smad4ﬂ/ﬂ;Dll4in3:Cre
embryos from E9.5 to P5. Only two sick (*) P5 Smad4ﬂ/ﬂ;Dll4in3:Cre animals were recovered. EC indicates Tie2:Cre-mediated deletion, ART indicates
Dll4in3:Cre-mediated deletion, da = dorsal aorta, nt = neural tube, cv = cardinal vein, ica = inner cerebral artery, isa = intersomitic arteries. See also
Supplementary Figure 3
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zebraﬁsh or relate to the high levels of proliferation seen in these
zebraﬁsh vessels31. In conclusion, this enhancer analysis clearly
demonstrates that the mouse Ephb4-2 sequence represents a
venous-speciﬁc enhancer for Ephb4 that closely mimics the
expression of the endogenous gene in mice, providing us with a
powerful tool to elucidate the regulators of Ephb4 in the venous
vasculature.
The Ephb4-2 enhancer requires SMAD-binding motifs. We
directly tested whether the Ephb4-2 enhancer was active in the
absence of endothelial SMAD4 by generating Smad4EC/EC;Tg
(Ephb4-2:LacZ) mouse embryos. Ephb4-2:LacZ expression was
largely absent in E10.5 Smad4EC/EC;Tg(Ephb4-2:LacZ) embryos,
similar to that seen with Ephb4LacZ (Fig. 5a and Supplementary
Fig. 5a–b). These results demonstrate that endothelial SMAD4 is
required for both endogenous Ephb4 expression and activity of
the Ephb4-2 enhancer.
The R-SMAD/SMAD4 complexes recognize a variety of DNA
sequences. These include the SMAD-binding element (SBE;
Supplementary Fig. 4b), and a variety of GC-rich sequences
primarily associated with the BMP-driven R-SMADS 1, 5 and
832,33. The SBE was initially identiﬁed as a motif bound by human
SMAD3 and SMAD4. However, SBE motifs are highly enriched
within ChIP-seq and ChIP-chip peaks after immunoprecipitation
with SMAD434,35, with TGF-β-associated R-SMAD SMAD336,37,
and with BMP-associated R-SMADs SMAD1/532 emphasizing
the commonality of this motif in DNA regions bound by different
types of R-SMAD/SMAD4 complexes. We therefore investigated
whether the Ephb4-2 enhancer sequence contained any con-
sensus or near-consensus SBEs (as deﬁned by JASPAR38). This
analysis identiﬁed nine potential binding motifs conserved
between human and mouse sequences (Supplementary Fig. 4c–d).
Mutation of all nine SBEs within the Ephb4-2 enhancer (Ephb4-
2mutSBEall) resulted in a massive reduction in vascular
expression in transgenic ﬁsh (Supplementary Fig. 5c–d). Of these
nine SBE, four occurred as part of palindromic repeat SBE
sequences (SBE2/3 and 6/7) commonly associated with SMAD
binding33. Mutations of these SBE2/3 and SBE6/7 sites separately
also resulted in near-total loss of the Ephb4-2 activity in transient
transgenic mice and zebraﬁsh (Fig. 5c and Supplementary
Fig. 5c–e). Similar mutations to other conserved regions away
from the SBEs and EBEs did not result in any alteration of
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Fig. 4 The vein-speciﬁc Ephb4-2 enhancer recapitulates endogenous Ephb4
expression in ﬁsh and mouse. a Region around the human EPHB4 gene as
seen on UCSC Browser (http://genome.ucsc.edu). Within histone marks,
the three tracks show the enhancer-associated H3K4Me1 and H3K27Ac
and promoter-associated H3K4Me3 marks found in human umbilical vein
endothelial cells as light blue peaks. Within DNaseI hypersensitivity, the
heat maps show DNaseI hypersensitive (HS) regions found in different cell
lines, with endothelial cells labelled in red and non-endothelial cells labelled
in orange. The endothelial histone marks and endothelial-speciﬁc DNase I
hypersensitivity indicate two potential endothelial enhancer regions
(named -2 and -10, marked as red horizontal lines). b, c The Tol2 Ephb4-2:
E1b:GFP transgene (b) directs venous expression of the green ﬂuorescent
protein (GFP) reporter gene in a transgenic zebraﬁsh line also expressing
the pan-endothelial kdrl:HRAS-mCherry (c). No enhancer activity (as
detected by GFP expression) was seen in the dorsal aorta, whereas robust
activity was detected in the cardinal and ventral veins. Expression is
detected in all intersegmental vessels. White scale bars are 100 μm. Red
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vein. d, e The Ephb4-2:hsp68:LacZ transgene (d) directs vein-speciﬁc
expression of the LacZ reporter gene in transgenic mice (e) as compared to
Ephb4LacZ/+. Black scale bars are 100 μm, grey scale bars are 500 μm,
red scale bars are 1000 μm. isv = intersomitic vessel, cv = cardinal vein,
da = dorsal aorta, jv = jugular vein, ca = carotid artery, ccv = common
cardinal vein, cev = branches of the cerebral venous plexus, lv = left
ventricle. See also Supplementary Figure 4
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expression (Supplementary Fig. 4c and 5c–d). In conclusion,
these analyses demonstrate that both endogenous Ephb4 and
Ephb4-2 enhancer activity requires SMAD4 and indicate an
essential role for SMAD4/R-SMAD-binding motifs for venous
expression of the Ephb4-2 enhancer.
SMAD1/5 binds Ephb4-2 to inﬂuence Ephb4 expression.
SMAD4 forms heteromeric transcriptional complexes with mul-
tiple different phosphorylated R-SMADS prior to nuclear trans-
location and direct DNA binding33. In mice, the combined
endothelial-speciﬁc deletion of the R-SMADs Smad1 and Smad5,
which are activated by BMP ligands, closely phenocopies the
vascular defects and early lethality seen in Smad4EC/EC embryos,
although this study ascribed the defective vasculature to an
angiogenic defect, not an arteriovenous one15. In contrast, com-
bined endothelial-speciﬁc deletion of Smad2/Smad3, activated by
TGF-β ligands, has no vascular effects at E10.5 and does not affect
survival until after E12.516. This suggests that SMAD4-mediated
venous identity involves the BMP-activated R-SMADs SMAD1
and SMAD5 (commonly written as SMAD1/5). Although
SMAD1 and 5 have high afﬁnity for SBE motifs, they prefer
alternative GC-rich binding motifs39. This was conﬁrmed by
Morikawa et al.32, who performed ChIP-seq analysis on HUVECs
stimulated with high levels of BMP9 to phosphorylate SMAD1/5.
This identiﬁed four over-represented motifs within SMAD1/5-
bound regions (reproduced in Supplementary Fig. 6a), only one
of which was localized around peak summits and therefore
assumed to directly bind SMAD1/5. This motif, summarized as
GGA/CGCC, was similar to the GCCG and GGCGCC SMAD1/5-
binding motifs described elsewhere39. In total, these GC-rich
elements (referred to as GC-SBE) were found in nearly half of all
SMAD1/5-bound motifs. This analysis also found signiﬁcant
enrichment of the SBE motif within SMAD1/5-bound regions,
and demonstrated that, when present, both SBE and GC-SBE
motifs were required for BMP responsiveness32. While the spacer
length between SBE and GC-SBE motifs varies between different
SMAD1/5-bound sequences, a 5 bp spacer between the two
motifs was over-represented in SMAD1/5-bound regions32.
Smad4+/+ Smad4EC/EC 
Tg(Ephb4-2:LacZ)a
Smad4+/+ Smad4EC/EC 
b
Trans tg(Ephb4-2WT:GFP) Zoom
ZoomTrans tg(Ephb4-2mSBE2/36/7:GFP)
c Ephb4-2WT Ephb4-2mutSBE
E10.5 E10.5 E10.5 E10.5
48hpf
48hpf
E11.5 E11.5 E11.5 E11.5 Transverse section
da
cv
nt
3/7 2/7 2/7
2/4 2/4
Fig. 5 Activity of the Ephb4-2 enhancer requires SMAD4. a Two sets of E10.5 Smad4+/+;Ephb4-2:LacZ and Smad4EC/EC;Ephb4-2:LacZ littermates
demonstrates loss of Ephb4-2 enhancer activity after loss of SMAD4 regardless of extent of growth retardation (n= 4 from 4 litters). Although some
embryos exhibited severe growth retardation, similar sized younger embryos had robust Ephb4-2:LacZ expression (see Supplementary Fig. 5). Grey scale
bars are 1000 μm. b, c Mutation of two composite SMAD-binding elements (SBE2/3 and SBE6/7) within the Ephb4-2 enhancer resulted in near-total loss
of enhancer activity compared to wild-type enhancer in F0 transgenic zebraﬁsh (b, mosaic due to nature of Tol2-mediated F0 transgenesis) and mice (c).
Transverse section taken through the strongest lacZ-expressing F0 Ephb4-2mutSBE(2/3,6/7) embryo conﬁrmed lack of vascular expression. Grey
numbers in bottom right corner indicate the number of F0 mouse with similar expression patterns to the image shown. White and black scale bars both
represent 100 μm, grey scale bars are 1000 μm. da = dorsal aorta, cv = cardinal vein, nt = neural tube; red bracket= dorsal artery; white bracket= axial
veins. See also Supplementary Figure 5
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To determine whether SMAD1/5 directly binds the Ephb4-2
enhancer, we examined the Ephb4-2 enhancer sequence for GC-
SBE SMAD1/5-binding motifs adjacent to the previously
identiﬁed SBE motifs. This analysis identiﬁed two conserved
SBE/GC-SBE composite motif elements and one additional non-
conserved SBE/GC-SBE motif element (Fig. 6a and Supplemen-
tary Fig. 6a). Strikingly, the 3’ conserved SBE/GC-SBE composite
element contains the SBE6/7 motif that we previously demon-
strated was required for Ephb4-2 enhancer activity (Fig. 5c). This
SBE/GC-SBE composite element contains the optimal 5 bp spacer
sequence separating the SBE and GC-SBE (Fig. 6a). The Ephb4-2
enhancer also contained numerous sequences correlating to the
other three SMAD1/5-bound region-associated motifs (Fig. 6a
and Supplementary Fig. 6a).
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Fig. 6 The Ephb4-2 enhancer is bound by SMAD1/5. a Mouse (m) and orthologous human (h) DNA sequence of the Ephb4-2 enhancer. Red nt on human
sequence correspond to regions bound by SMAD1/5 as determined from SMAD1/5 human umbilical vein endothelial cell (HUVEC) chromatin
immunoprecipitation-sequencing (ChIP-seq) data32 (see also Supplementary Fig. 6c). Green boxes denote GC-SBE motifs associated with SMAD1/5
binding, blue boxes denote SBE motifs associated with all SMAD binding and grey boxes denote other over-represented motifs (MEME1, 3 and 532). Black
outlined boxes denote composite SBE/GC-SBE elements, italic nt indicate linker sequences. Grey text under sequences indicates motifs previously
identiﬁed as the EBEs and SBEs in earlier analysis (Supplementary Fig. 4). For sequence logos of motifs, see Supplementary Fig. 6b. b SMAD1/5 HUVEC
and PASMC ChIP-seq data from Morikawa et al.32 (red peaks= statistically signiﬁcant peaks after BMP9 stimulation in HUVEC). Signiﬁcant binding peaks
are not observed in PASMC after BMP4 stimulation (green). See also Supplementary Fig. 6c). c Box and whiskers plot of ChIP-qPCR data shows signiﬁcant
enrichment of SMAD1 binding at the Ephb4-2 enhancer in BMP9-stimulated HUVECS (red) compared to a control intergenic region on the same
chromosome (p= 0.00015, paired two-tailed t test). SMAD1 binding at the Ephb4-2 enhancer region is not enriched over control in the absence of BMP
stimulation (green) (p= 0.19212). No enrichment is observed between IgG control regions (p= 0.3154 and p= 0.19212, paired two-tailed t test).
Horizontal lines=medians, boxes= interquartile range (IQR); vertical lines=minimal/maximal values (up to 1.5× IQR) and black dots= data points
outside of 3× IQR. Data represents three biological replicates each with three technical replicates performed in triplicate. All data points were included in
statistical analysis. d, eMorpholino (MO)-mediated partial knockdown of smad1/5 on GFP expression in arterial tg(Dll4in3:GFP) (d) and venous tg(Ephb4-2:
GFP) (e) transgenic zebraﬁsh lines, using 0.5 ng smad1 MO and 0.25 ng smad5 MO. Graphs depict expression in all embryos, Dll4in3:GFP WT n= 58, MO
n= 48; Ephb4-2:GFP WT n= 104, MO n= 84. High expression= solid colour, weak= pattern, absent= solid white. Zebraﬁsh embryos shown are
representative of the predominant phenotype, red bracket= dorsal aorta, white bracket= posterior cardinal and ventral vein(s). White scale bars represent
100 μm
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To further determine whether phosphorylated SMAD1/5
directly binds the Ephb4-2 sequence, we re-examined the
HUVEC SMAD1/5-binding data generated by Morikawa
et al.32. In agreement with our motif analysis, signiﬁcant EC-
speciﬁc binding peaks for SMAD1/5 were found directly over the
two conserved regions of the orthologous human EPHB4-2
enhancer sequence (Fig. 6b and Supplementary 6b–c). The ability
of SMAD1/5 to bind these enhancers was further conﬁrmed by
ChIP quantitative polymerase chain reaction (qPCR) using the
same conditions as in Morikawa et al.32 (Fig. 6c). No other
SMAD1/5-binding peaks were found elsewhere in the Ephb4 gene
locus (Supplementary Fig. 6b).
To determine whether reduction in SMAD1/5 levels affected
Ephb4-2 activity, we examined the consequences of morpholino
(MO)-mediated smad1/5 knockdown on Ephb4-2:GFP in trans-
genic zebraﬁsh. While the effects of complete deletion of smad1/5
on Ephb4-2 could not be investigated owing to severe patterning
defects40, we were able to knockdown smad1/5 in tg(Ephb4-2:
GFP) zebraﬁsh using lower doses of smad1 and smad5 MO40.
These MOs adhere to current guidelines41, in that they
recapitulate the mutant phenotype, give similar results to other
MOs targeting the same gene and can be rescued by RNA
expression40. Knockdown of smad1/5 resulted in near-complete
ablation of Ephb4-2:GFP activity in the trunk and segmental
vessels (Fig. 6d and Supplementary Fig. 7a). All embryos also had
a dorsalization defect that signiﬁcantly affected the tail region and
grew more severe with high MO doses, invalidating any analysis
of venous structures in these morphants. However, expression of
the arterial-speciﬁc Dll4in3:GFP transgene was still robust in the
tail region of MO-treated embryos, suggesting that a pan-vascular
defect was unlikely to explain the loss of Ephb4-2:GFP
expression. A dose–response curve (with total MO concentration
ranging from 0.375 to 1.5 ng), demonstrated both increased
dorsalization and decreased Ephb4-2:GFP activity as MO
concentrations increased (Supplementary Fig. 7b–c). Loss of
Ephb4-2:GFP after smad1/5 knockdown was also unlikely to be
related to reduction of blood ﬂow, as Ephb4-2:GFP expression
was not signiﬁcantly affected in tnnt2 morphants, which have no
heartbeat (Supplementary Fig. 7d). Whole-mount in situ analysis
in these morphants was used to also examine the expression
patterns of endogenous ephb4a, dll4 and the arterial marker
ephb2a: arterial dll4 and ephb2a was detected in smad1/5
morphants, while ephb4a expression was greatly reduced
(Supplementary Fig. 8). Although it is unwise to make deﬁnitive
conclusions based on MO-based knockdown analysis alone, these
results were strikingly similar to those seen in Smad4EC/EC mice.
Consequently, when combined with enhancer sequence analysis,
ChIP-seq and ChIP-qPCR results, our data strongly support a
direct role for SMAD1/5–SMAD4 in the regulation of venous
Ephb4 expression.
SMAD1/5 regulates transcription of venous-speciﬁc genes.
Although phosphorylated SMAD1/5 (pSMAD1/5) can be detec-
ted in both venous and arterial ECs42 (Supplementary Fig. 9a),
the Id1 promoter-based BMP response element (BRE, containing
SBE and GC-SBE motifs)43 has been reported to be preferentially
expressed in the zebraﬁsh caudal vein comparative to the dorsal
aorta44,45 and is more strongly and consistently expressed in
mouse cardinal vein ECs (E11.5) and postnatal retinal veins (P4)
comparative to arterial ECs46. Further, analysis of the HUVEC
SMAD1/5 ChIP-seq data by Morikawa et al.32 found signiﬁcant
SMAD1/5 binding within only two of the 11 in vivo-characterized
pan-endothelial enhancers (Supplementary Fig. 9b), and no
SMAD1/5-binding peaks within any of the six known arterial
gene enhancers (Supplementary Fig. 9c). This suggests that
SMAD1/5 binding is not strongly associated with pan-EC or
arterial gene expression, even though HUVECs express many
arterial-associated genes47, including the BMP type I receptor
ALK1 (ACVRL1) through which BMP9 can signal32,48. This
result therefore indicates that, unlike ETS factors, SMAD1/5
binding is not an essential component of all endothelial
enhancers.
The loss of venous structures in Smad4EC/EC embryos suggests
the possibility that SMAD4–SMAD1/5 binding may be a shared
feature of venous-expressed genes. Supporting this hypothesis,
our re-examination of the HUVEC SMAD1/5 binding31 found
SMAD1/5-bound peaks within the loci of the venous-associated
Coup-TFII (Nr2f2), Nrp2 and Emcn genes (Fig. 7a and
Supplementary Fig. 10a). In each case, SMAD1/5 binding
coincided with enhancer-associated histone marks, DNaseI
hypersensitivity and sequence motifs for both ETS (EBE) and
SMAD (SBE and GC-SBE) (Fig. 7a and Supplementary
Fig. 10a–b), suggesting that these sequences may represent
endothelial enhancers. Supporting this hypothesis, the CoupTFII-
965, Nrp2+26 and EMCN-22 enhancers were all able to direct
endothelial-speciﬁc LacZ activity in transgenic mice (Fig. 7b and
Supplementary Fig. 10c–d).
Coup-TFII, like Ephb4, is speciﬁcally expressed in venous but
not arterial ECs, where it is essential for vein acquisition and
identity in early embryonic development7. Similar to the Ephb4-2
enhancer, the CoupTFII-965 enhancer was able to drive venous
endothelial-speciﬁc reporter gene expression in both transgenic
mice and transgenic zebraﬁsh lines (Fig. 7b, c and Supplementary
Fig. 11a–c). Unlike Ephb4-2, CoupTFII-965 expression was also
seen in the early dorsal aorta (E8.5 and 24 hpf) and paraxial
mesoderm (E9.5 and 24 hpf) in both mouse and zebraﬁsh
transgenic models (Fig. 7b and Supplementary Fig. 11a),
suggesting that CoupTFII-965 may bind additional factors not
shared with Ephb4-2 that regulate non-venous endothelial
activity. Although we could not independently verify SMAD1/5
binding to the CoupTFII-965 enhancer region, analysis of the
CoupTFII-965 enhancer sequence identiﬁed three conserved
consensus SBE-binding motifs, the second of which was located
within a core SMAD1/5-binding peak (Supplementary Fig. 10b
and 11d). Unlike Ephb4-2, no conserved GC-SBE motifs were
found surrounding these SBE sites, although non-conserved GC-
SBE were separately identiﬁed in both human and mouse
sequences (Supplementary Fig. 11d). To determine whether the
core SBE (SBE-peak) was required for CoupTFII-965 activity, we
tested enhancers in which this motif was mutated. Expression of
the CoupTFII-965 enhancer was entirely ablated after mutation of
SBE-peak in both mouse and zebraﬁsh transient transgenic
models (Fig. 7d). As with Ephb4-2, alternative mutations within
the CoupTFII-965 enhancer away from the EBEs and SBEs did
not signiﬁcantly inﬂuence activity (Fig. 7d). Therefore, although
these results cannot prove SMAD1/5 binding to the COUPTFII
enhancer, they suggest that SMAD-mediated activation may be a
shared feature of both Ephb4 and Coup-TFII gene expression in
veins.
The BMP type I receptor ALK3 is required for vein formation.
We hypothesized that either repression of BMP-driven gene
activation in early arterial ECs or spatially selective expression of
BMP receptors may contribute to venous-speciﬁc gene expres-
sion. We found no evidence of arterial repression of BMP-driven
venous gene activation via known pathways. Speciﬁcally, chemi-
cal inhibition of ERK/MAPK signalling, which is active in arteries
but repressed in veins6 and had previously been associated with
inhibition of nuclear SMAD149, did not lead to arterial expansion
of Ephb4-2:GFP expression (Supplementary Fig. 12a). Similarly,
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Notch signalling can repress BMP responsiveness through the
activation of SMAD6 in the angiogenic sprout50, yet inhibition of
Notch had no effect on the intensity and vein speciﬁcity of
Ephb4-2:GFP and CoupTFII-965:GFP expression, although the
expected hyper-sprouting phenotype was observed (Fig. 8a and
Supplementary Fig. 12b)51. We also found little evidence that
spatial restriction of BMP type II receptors played a crucial role in
early venous identity. Wiley et al. demonstrated that zebraﬁsh
BMP type II receptors bmpr2a and bmpr2b (BMPR2 in mice) are
important regulators of venous angiogenic sprouting18. However,
when we repeated their MO-induced depletion of bmpr2a and
bmpr2b in tg(Ephb4-2:GFP) zebraﬁsh, we did not lose enhancer
activity and could still see a developed axial vein although we
recapitulated the venous sprouting defect (Supplementary
Fig. 12c). Similarly, Kim et al.44 reported an essential role for
dab2 as a mediator of BMP2 signalling in zebraﬁsh venous
sprouting. However, again when we repeated their MO-induced
depletion of dab2 in tg(Ephb4-2:GFP) zebraﬁsh we saw little
change in enhancer activity or axial vein formation although we
again recapitulated the venous sprouting defect (Supplementary
Fig. 12c). While the initial design of these MOs may not meet the
current standards in all cases, mice lacking endothelial BMPR2
also exhibit no reported embryonic vascular defects39, strongly
suggesting that BMPR2 is unlikely to be absolutely required for
early Ephb4 expression or venous identity. Since the other BMP
type II receptors, Acvr2a and Acvr2b, are ubiquitously expressed
during arteriovenous differentiation52, it is therefore unlikely that
spatial restriction of type II receptors alone is responsible for vein
identity during embryonic development.
To investigate a potential role of BMP type I receptors in Ephb4
expression, we ﬁrst investigated Ephb4-2:GFP activity after
addition of the chemical inhibitor DMH1. DMH1 speciﬁcally
targets the BMP type I receptors ALK1 (ACVRL1), ALK2
(ACVR1), ALK3 (BMPR1A) and ALK6 (BMPR1B). Treatment of
tg(Ephb4-2:GFP) embryos with DMH1 (at a dose that did not
cause severe patterning defects) resulted in signiﬁcantly reduced
Ephb4-2:GFP activity (Supplementary Fig. 12d), suggesting a
requirement for one or more of these receptors in venous identity.
Unlike the early vascular defects and lethality seen in Smad4EC/EC
and Smad1/5EC/EC mice, Alk6 null mice are born healthy at
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Fig. 7 A SMAD1/5-binding peak identiﬁes a vein endothelial enhancer for Coup-TFII. a UCSC browser view (http://genome.ucsc.edu) of COUP-TFII (NR2F2)
incorporating SMAD1/5-binding data from Morikawa et al.32. A statistically signiﬁcant SMAD1/5-binding peak in human umbilical vein endothelial cells
(HUVECs) (red) −965 kb upstream of Coup-TFII correlated with the H3K27Ac enhancer histone mark in HUVECs (blue peaks) and endothelial HUVEC
DNaseI hypersensitivity (black heat map). b, c Stable transgenic mouse (b) and zebraﬁsh (c) embryos expressing the lacZ and GFP reporter genes,
respectively, under the control of the murine CoupTFII-965 enhancer. In both animal models, enhancer activity was primarily seen in the venous
endothelium. Black and white scale bars both represent 100 μm, grey scale bars are 500 μm, red scale bars are 1000 μm. a = artery, v = vein, cev =
branches of cerebral venous plexus, cv = cardinal vein, pm = paraxial mesoderm, da = dorsal aorta, red bracket= dorsal aorta; white bracket= posterior
cardinal and ventral vein(s). d Tables summarizing reporter gene expression in transient transgenic zebraﬁsh and mouse embryos after mutation of the
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Fig. 8 Notch-independent Alk3a/b signalling is involved in venous identity in zebraﬁsh. a Loss of Notch signalling had no effect on the expression of the
venous Ephb4-2:GFP transgene in tg(Ephb4-2:GFP) transgenic zebraﬁsh. Representative 48 hpf embryos demonstrate similar intensities of vein-speciﬁc
green ﬂuorescent protein (GFP) expression in both control and DAPM-treated embryos. Red bracket= dorsal aorta, white bracket= posterior cardinal and
ventral vein. Graph depicts observed expression pattern of GFP in tg(Ephb4-2:GFP) embryos for control (n= 51) and 100 µM DAPM-treated embryos
(n= 57); black denotes high expression, grey denotes weak. See Supplementary Fig. 12 for Coup-TFII-965:GFP results and controls. b Morpholino (MO)-
induced reduction of alk1 and alk2 had little effect on Ephb4-2:GFP expression in 48hpf tg(Ephb4-2:GFP) transgenic zebraﬁsh, whereas reduction of alk3a/b
resulted in signiﬁcantly decreased transgene expression. Representative 48 hpf tg(Ephb4-2:GFP) embryos demonstrate reduced GFP expression after
alk3a/b MO injection. Red bracket= dorsal aorta, white bracket= posterior cardinal and ventral vein. Graph depicts observed expression patterns of GFP
for control (n= 51), alk1 MO (n= 45), alk2 MO (n= 45) and alk3a/b MO (n= 48); black denotes high expression, grey denotes weak expression and white
denotes no detectable GFP expression. cWhole-mount in situ hybridization for bone morphogenetic protein (BMP) receptors alk3a and alk3b compared to
pan-endothelial kdrl in wild-type zebraﬁsh embryos at 20, 24, 28 and 36 hpf. Earlier time points can be seen in Supplementary Fig. 13. Both alk3a and alk3b
were detected in the axial vein but not in the artery, with greater early expression seen for alk3b. Red bracket= axial artery, blue bracket= axial vein.
d Whole-mount in situ hybridization for BMP ligands bmp2b and bmp4 compared to pan-endothelial kdrl in wild-type zebraﬁsh embryos at 28 hpf. Both
bmp2b and bmp4 showed stronger expression around the axial veins comparative to the dorsal artery. Red bracket= axial artery, blue bracket= axial vein.
All scale bars represent 100 μm. See also Supplementary Figures 12–13
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Mendelian ratios with no reported vessel defects53. Consequently,
we ruled out a potential essential role for ALK6 in embryonic vein
development. However, individual loss of Alk1, Alk2 and Alk3 in
mice each results in embryonic lethality with some degree of
vascular defects12,54,55, warranting further investigation.
To determine which ALK receptor(s) are required for venous
identity, we ﬁrst conducted a zebraﬁsh screen, looking at the
effects of reducing levels of the zebraﬁsh orthologues of ALK1, 2
and 3 individually in tg(Ephb4-2:GFP) ﬁsh using MOs known to
recapitulate mutant phenotypes. These experiments used reduced,
sub-lethal concentrations of MOs where necessary to avoid
previously reported gastrulation defects56,57, effectively creating a
knockdown but not full depletion. The alk1 and alk2 morphants
maintained reporter gene activity in the posterior cardinal vein
despite considerable morphological defects (Fig. 8b). In contrast,
Ephb4-2:GFP expression was severely diminished in combined
alk3a/b morphants (Fig. 8b and Supplementary Fig. 13a). The
alk3a and alk3b MO used here recapitulate the zygotic mutant
phenotype and can be rescued by RNA injection56,58. As with
smad1/5 MO, a dose–response curve was also included in the
analysis (Supplementary Fig. 13a–b).
The loss of Ephb4-2:GFP expression in alk3a/b morphants
suggested a potential role in venous gene expression. We
therefore investigated the expression pattern of alk3a/b in early
zebraﬁsh embryos. Although not previously reported to be
strongly expressed in the zebraﬁsh vasculature58, we detected
expression of alk3b in venous positioned angioblasts from 18 to
20 s (approximately 18 hpf), and both alk3a and alk3b were
highly expressed in venous regions of the axial vasculature by 28
hpf (Fig. 8c and Supplementary Fig. 13c). In comparison, we
detected little expression of endogenous ephb4a until 20 s
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Fig. 9 Endothelial-speciﬁc knockout of Alk3 results in loss of venous identity
in mice. a, b. Immunoﬂuorescent analysis of CD31, EPHB4 and ALK3
(a) and in situ hybridization for Bmp4 (b) in transverse sections from
E9.5 mouse embryos. Scale bars are 50 μm. c Representative E10.5 whole-
mount images from wild-type Alk3+/+ (n= 16), heterozygous Alk3EC/+;
(n= 7) and homozygous Alk3EC/EC (n= 7) embryos expressing the arterial
Dll4in3:LacZ transgene (Nine litters). Robust transgene expression, speciﬁc
to arterial endothelial cells, was seen in all embryos although Alk3EC/EC
embryos were often signiﬁcantly growth retarded. Grey numbers on bottom
right denote the number of embryos similar to picture shown; for Alk3EC/EC,
two different images show Dll4in3:LacZ expression in the range of
morphological defects. Grey scale bars are 500 μm. d Representative E10.5
whole-mount images from wild-type Alk3+/+ (n= 34), heterozygous
Alk3EC/+; (n= 21) and homozygous Alk3EC/EC (n= 16) embryos expressing
venous Ephb4LacZ (21 litters, for littermates, see Supplementary Fig. 16).
Robust X-gal activity is detected in the veins of Alk3+/+ embryos but is
reduced in Alk3EC/+ embryos and absent in Alk3EC/EC regardless of extend
of growth retardation and morphological defects. Grey numbers on
bottom right denote the number of embryos similar to picture shown; for
Alk3EC/EC, two different images are shown to indicate Ephb4LacZ expression
in the range of morphological defects. Grey scale bars are 500 μm.
e Representative transverse sections from E10.5 Alk3EC/EC embryos
transgenic for either arterial Dll4in3:LacZ or venous Ephb4LacZ at two
different levels. Some vessels were clearly seen in both; these expressed
Dll4in3:lacZ but not Ephb4LacZ and were located in arterial positions,
suggesting the presence of dorsal aorta but no cardinal vein. Black scale
bars are 100 μm. f, g Representative arterial endothelial-speciﬁc Alk3+/+
and Alk3ART/ART whole-mount E10.5 embryos (f) and transverse sections
stained with CD31 (g). Loss of Alk3 in arterial endothelial cells had no effect
on vascular development at E10.5. White scale bars are 100 μm.
h Observed frequency of Alk3ﬂ/ﬂ;Dll4in3:Cre embryos at E10.5 and P5.
Mendelian ratios were present at both time points. For all panels, EC is Tie2:
Cre-mediated deletion, ART is Dll4in3:Cre-mediated deletion. +/+ indicates
Cre−, EC/+ indicates Cre+,Alk3ﬂ/+ and EC/EC indicates Cre+;Alk3ﬂ/ﬂ.
da= dorsal aorta, ica= internal carotid artery, isa= intersomitic arteries,
isv= intersomitic vessels, baa= branchial arch arteries, nt= neural tube,
cv= cardinal vein, cev= branches of cerebral venous plexus,
mda=midline dorsal aorta
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(approximately 19–20 hpf; Supplementary Fig. 13d), suggesting
alk3a/b expression begins concurrently or just before that of
ephb4a. The expression of known ALK3 ligands bmp2b and bmp4
were also highest around the developing trunk vein18 (Fig. 8d).
Further, MO-induced depletion of alk3a/b resulted in signiﬁcant
reduction in endogenous ephb4a expression (Supplementary
Fig. 14a–c), while morphological analysis of alk3a/b morphants
demonstrated the presence of only one axial vessel and a lack of
proper blood circulation (Supplementary Fig. 14d). These results
therefore suggest that the spatially restricted ALK3 receptors may
play a fundamental role in ephb4 expression and vein
morphogenesis in zebraﬁsh.
Endothelial-speciﬁc loss of Alk3 (Bmpr1a) in mice results in
early vascular defects similar to Smad4EC/EC embryos12, support-
ing a speciﬁc role for ALK3 in venous identity in mammals as
well as zebraﬁsh. Comparatively, endothelial deletion of the
vascular type I receptors Alk1(Acvrl1) and Alk2 (Acvr1) caused
later lethality55,59. Analysis of murine ALK3 expression also
found that it was preferentially found in venous ECs relative to
arterial endothelium at E8.5 and E9.5 (Fig. 9a and Supplementary
Fig. 15a). Further, expression of the ALK3 ligand Bmp4 was also
preferentially found around venous vessels (Fig. 9b and
Supplementary Fig. 15b). Although the vascular defects seen
after endothelial-speciﬁc Alk3 deletion were previously attributed
to defective vessel maturation and problems in atrioventricular
endocardial cushion formation12, arteriovenous differentiation
was not investigated in these embryos. Therefore, we re-
investigated the consequences of endothelial-speciﬁc ablation of
Alk3 in mice. As with Smad4EC/EC embryos, Tie2:Cre-mediated
deletion of Alk3 (Alk3EC/EC) resulted in severe defects by E10.5
but did not ablate expression of the arterial-associated Dll4in3:
LacZ transgene (Fig. 9c, e). However, no expression of Ephb4LacZ
was detected in any Alk3EC/EC embryos by E10.5 (Fig. 9d, e).
Morphological analysis of Alk3EC/EC;Dll4in3:LacZ and Alk3EC/EC;
Ephb4LacZ embryos conﬁrmed that these embryos contain
Dll4in3:LacZ+ dorsal aortas but lack both Ephb4LacZ-positive
vessels (Fig. 9e). Although many of these embryos were
substantially defective by E10.5, all heterozygous Alk3EC/+
embryos also showed consistently reduced levels of Ephb4LacZ
expression, although they exhibited no clear morphological
defects (Fig. 9d). Strikingly, deletion of Alk3 using the arterial
expressed Dll4in3:Cre (Alk3ART/ART) had little effect on embryos
at E10.5 (Fig. 9f–h), demonstrating that, similar to Smad4EC/EC,
the vascular defects seen in Alk3EC/EC embryos are not caused by
general vascular maturation or cardiac defects. Previous analysis
also found no defects in haematopoiesis in Alk3EC/EC embryos12.
Because the ALK3 receptor is speciﬁc for the BMP pathway and
signals only through SMAD1/5/860, these mutant mouse experi-
ments also provide direct in vivo murine evidence supporting our
zebraﬁsh smad1/5 MO-mediated observations linking SMAD1/5
with the regulation of Ephb4 and venous identity. In conclusion,
these results support a model of arteriovenous development in
which the venous-restricted ALK3 receptor is indispensable for
vein morphogenesis downstream of BMP ligands and upstream of
SMAD4–SMAD1/5-dependent transcriptional activation of
venous genes (Fig. 10).
Discussion
The crucial roles for VEGF-A and NOTCH in activating arterial
EC identity has often led to the supposition that venous speciﬁ-
cation is either default or actively repressed in arteries. However,
our results clearly demonstrate that venous genes are directly
transcriptionally activated via a BMP/ALK3/SMAD1/5 signalling
cascade. This therefore supports a model for arteriovenous dif-
ferentiation in which endothelial progenitors positively acquire
either arterial or venous fate downstream of independent sig-
nalling pathways early in development.
The speciﬁc expression of the Alk3 type I receptor and Bmp2/4
ligands in venous ECs suggests that venous ECs may be innately
sensitive to BMP signalling45. Supporting this, the type II BMP
receptors Bmpr2a and Bmpr2b and cargo-speciﬁc adaptor Dab2
are also enriched in zebraﬁsh venous ECs18,44. Although neither
BMPR2a/b nor DAB2 appeared to be absolutely required for
Ephb4-2 activity or venous speciﬁcation, the combined expression
of these BMP signalling components in addition to ALK3 may
well contribute to an increased venous endothelial response to
BMP ligands. It is also possible that the type I receptor ALK2
(ACVRL1) contributes to venous differentiation at later stages of
embryogenesis and after birth: while endothelial-speciﬁc loss of
Alk2 did not phenocopy the early vascular defects seen in Sma-
d4EC/EC or Alk3EC/EC embryos, ALK2 is implicated in venous
angiogenesis alongside ALK3 in zebraﬁsh18 and is strongly
expressed in venous ECs in the postnatal retina, where Alk2 and
Alk3 are required for correct retinal vessel morphogenesis61.
The results in this paper strongly indicate that the establish-
ment of venous identity is the principle function for BMP sig-
nalling in the early vasculature. In particular, the absence of
detectable vascular defects in E10.5 Smad4ART/ART embryos
suggests that many of the previous roles attributed to BMP sig-
nalling via SMAD4 in ECs, including vascular integrity, remo-
delling and smooth muscle recruitment12,14, may be secondary to
the loss of correct arteriovenous speciﬁcation and resultant
breakdown of vascular patency. While we did not directly
investigate cardiac valve defects, both Alk3ART/ART and Smad4
ART/ART embryos survived until late gestation despite endocardial
expression of Dll4in3:Cre, indicating that the requirement for
BMP signalling in cardiac valve formation may manifest in death
at later embryonic stages. This does not necessarily suggest that
BMP signalling is unimportant for valve morphogenesis: endo-
cardial nuclear factor of activated T cell (NFAT) signalling is
absolutely required for heart valve morphogenesis, yet endothelial
NFAT-deﬁcient embryos display aberrant valves and gestational
lethality only after E13.562. Similarly, our results do not directly
contradict a role for BMP-SMAD1/5 in angiogenic sprouting15,22.
While the Dll4in3:Cre used to generate Smad4ART/ART embryos is
also active in ECs at the angiogenic front, Dll4in3 is preferentially
BMP
ALK3
(BMPR1a)
pSMAD1/5
Ephb4
Nr2f2/Coup-TFII
Venous identity
Fig. 10 Proposed model. Our data support a model in which vein-enriched
bone morphogenetic protein (BMP) ligands BMP2 and BMP4 signal
through the vein-speciﬁc Alk3 type I receptor (in combination with multiple
different BMP type II receptors) resulting in the phosphorylation of
SMAD1/5, transcriptional activation of the Ephb4 and Coup-TFII genes and
subsequent venous identity
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active in tip cells21. Conversely, the angiogenic role of BMP sig-
nalling is thought to occur primarily in stalk cells, where it co-
operates with the Notch pathway15,22. Agreeing with this role,
endothelial SMAD1/SMAD5 binding was also enriched around
Notch pathway genes, although not over the three characterized
arterial Notch-pathway enhancers (this paper and ref. 32). How-
ever, recent reports in zebraﬁsh demonstrate that venous ECs are
the primary source of cells at the angiogenic front63, suggesting
that it may be impossible to entirely separate the requirement of
SMAD1/5 in venous identity with any potential role in embryonic
angiogenic sprouting.
SMAD1/5 is involved in many other BMP-driven processes
beyond the vasculature, suggesting that any recruitment of
SMAD4–SMAD1/5 to venous enhancers would require additional
cofactors33,64. The presence of ETS-binding motifs (EBEs)
alongside SMAD motifs in each venous enhancer suggests a role
for ETS transcription factors such as ERG, which are already
established as central regulators of endothelial gene expression25,
in conferring endothelial speciﬁcity to SMAD1/5-bound vein
enhancers. These may potentially assist SMAD complexes in
binding DNA, as alone they have only low afﬁnity for DNA33.
However, ETS factor binding is also a feature of pan-endothelial,
arterial and angiogenic enhancers19–21, making it unlikely that
ETS factors contribute directly to venous speciﬁcity.
Although ligand and receptor density or speciﬁcity may result
in increased venous pSMAD1/5 during early arteriovenous
development18, some BMP receptors are clearly expressed in both
mouse and zebraﬁsh arteries (e.g. ALK1)65,66, and HUVEC
SMAD1/5 ChIP analyses demonstrate that BMP9, more com-
monly associated with ALK1-mediated angiogenesis, can stimu-
late SMAD1/5 to bind to venous enhancers in vitro. Nuclear
pSMAD1/5 is also found in both arterial and venous ECs, yet
both Ephb4-2 and CoupTFII-965 enhancers were predominantly
speciﬁc to venous endothelium. It is therefore highly probable
that additional co-factors cooperate with ETS and SMAD1/5 to
activate speciﬁc genes in veins and/or to repress these genes
elsewhere. There is already some evidence supporting a role for
direct transcriptional activation and repression in SMAD1/5-
dependent vein-speciﬁc gene expression: the Id1-based BRE,
effectively a group of SBE and GC-SBE motifs, is virtually silent in
the vasculature unless additional cytomegalovirus (CMV)-derived
enhancer elements are added to the transgene67. Further, activity
of the BRE-CMV is enriched but not speciﬁc to the venous
endothelium. These observations therefore suggest that DNA
motifs binding both activating and repressive transcription fac-
tors may be needed in addition to SBE and GC-SBE elements to
achieve vein-speciﬁc gene activation.
Our results also present a compelling case for ALK3 to be
considered as a target for antiangiogenic therapy. Current anti-
angiogenic drugs, which aim to prevent the rapid vessel growth
seen during tumourigenesis, primarily target the VEGF signalling
pathway. However, the response is often limited and additional
therapeutic targets are needed68. Combined with the emerging
understanding of the importance of the venous endothelium at
the angiogenic front63, the essential and independent role for
ALK3 in venous growth demonstrated here suggests that target-
ing of ALK3 may effectively inhibit tumour angiogenesis.
Methods
Cloning. For venous enhancers, all enhancer sequences were initially generated as
custom-made, double-stranded linear DNA fragments (GeneArt® Strings™, Life
Technologies) with the exception of Coup-TFII-965 and Nrp2+26, which were
generated by PCR from genomic DNA. The sequences of all enhancers are pro-
vided in Supplementary Methods. DNA fragments/PCR products were cloned into
the pCR8 vector using the pCR8/GW/TOPO TA Cloning Kit (Invitrogen, K2500-
20) following the manufacturer’s instructions. Once cloning was conﬁrmed, the
enhancer sequence was transferred from the pCR8/GW/enhancer entry vector to a
suitable destination vector using Gateway LR Clonase II Enzyme mix (Life Tech-
nologies, 11791-100) following the manufacturer’s instructions. For mouse trans-
genesis, the enhancer was cloned into the hsp68-LacZ-Gateway vector (provided by
N. Ahituv). For zebraﬁsh transgenesis, the enhancer was cloned into the E1b-GFP-
Tol2 vector (provided by N. Ahituv).
To generate the Dll4in3Cre transgene, the Dll4in3 enhancer19 was ampliﬁed by
PCR to include engineered 5’ SacII and 3’ Not1 restriction sites (sequences in
Supplementary table 1) and cloned into the promoterless p-AUG-βGal construct69.
The Dll4in3 promoter was also generated by PCR with engineered 5’ SpeI and 3’
BamHI sites (sequences in Supplementary Methods) and cloned into the Dll4in3
enhancer–p-AUG-βGal construct. Transgenic mice were generated to ensure
activity of enhancer/promoter construct, after which the βGal sequence was
replaced by Cre-ORT/polyA ampliﬁed from the pCAG-Cre vector. The full
sequence of the Dll4in3 enhancer/promoter is provided in Supplementary
Methods.
Mice. All animal procedures comply with all relevant ethical regulations, were
approved by the Clinical Medicine Local Ethical Review Committee, University of
Oxford and licensed by the UK Home Ofﬁce. Smad4ﬂ/ﬂ mice70–73 were provided by
Elizabeth Robertson, Tg(Tie2:Cre) mice, ofﬁcially designated Tg(Tek-cre)12Flv/J74,75,
were purchased from JAX (stock number 004128), Ephb4LacZ/+ mice5,76 were
provided by David Anderson, Cdh5(PAC)-CreERT2 mice23 were provided by Ralf
Adams and Alk3ﬂ/ﬂ mice12 were provided by Yuji Mishina. Tg(Dll4in3:LacZ) were
as described in refs. 19,32, while the Tg(Ephb4-2:LacZ), Tg(Coup-TFII-965) and Tg
(Dll4in3:Cre) lines were generated for this paper. Transgenic mice were generated
by oocyte microinjection of linearized DNA77,78. Mouse embryos were collected
along with yolk sac and ﬁxed in 2% paraformaldehyde (PFA), 0.2%
glutaraldehyde and 1× phosphate-buffered saline (PBS). E8.5 embryos were ﬁxed
at 4 °C for 10 min, E9.5 embryos ﬁxed for 30 min, E11.5 embryos for 60 min
and E13-E15 embryos for 120 min. After ﬁxation, embryos were rinsed in 0.1%
sodium deoxycholate 0.2% Nonidet P-40 2 mM MgCl2 1× PBS and then stained
for 2–24 h in 1 mg/ml 5-bromo-4-chloro-3-indolyo-β-D-galactoside solution
(X-gal) containing 5 mM potassium ferrocyanide, 5 mM ferricyanide, 0.1% sodium
deoxycholate, 0.2% Nonidet P-40, 2 mM MgCl2 and 1× PBS. After staining,
embryos were rinsed through a series of 1× PBS washes, then ﬁxed overnight in 4%
PFA at 4 °C. Embryos were imaged using a Leica M165C stereo microscope
equipped with a ProGres CF Scan camera and CapturePro software (Jenoptik).
In instances that images have been altered to improve quality and colour balance,
each image within a set (e.g. WT, het and null embryos) have been altered using
the same parameters. This occasionally included to selective depletion of the
yellow or red colour channel, in order to counteract issues from the X-gal stain
solution (which is orange). All embryos are stored in 4% PFA indeﬁnitely and
slowly become less yellow. Consequently, embryos stained more recently have a
greater yellow/orange hue. An example of this alteration can be seen in Supple-
mentary Figure 16.
The yolksac was used for genotyping. Tissue samples were incubated overnight
at 55 °C with 500 μl GNT buffer (50 mmol/l KCl, 1.5 mmol/l MgCl2, 10 mmol/l
Tris-pH8, 0.01% gelatin, 0.45% nonidet P40, 0.45% Tween) and proteinase K
(10 mg/ml); 0.5 μl of this supernatant was subsequently used in PCR reactions
with the GoTag Green master mix (Promega, M7122) using relevant PCR primers.
For Smad4EC/EC crosses with Ephb4Lacz/+ and Ephb4-2:LacZ, in the rare cases
where the LacZ genotyping results did not agree with the pattern of X-gal
staining in WT embryos, error was presumed and the entire litter was excluded.
For histological analysis of transgenic and mutant mouse sections, embryos
were dehydrated through a series of ethanol washes, cleared by xylene and parafﬁn
wax-embedded. Five or 6-μm sections were prepared and de-waxed. For imaging
of X-gal staining, slides were counterstained with nuclear fast red (Electron
Microscopy Sciences). Analysis was qualitative not quantitative, therefore no
statistical analysis was applied to the observations of staining intensity and pattern.
Numbers of transgenic mice used followed precedent set by similar published
papers. Where signiﬁcant variations in expression were detected within a single
experimental set, this is represented in the relevant ﬁgure by representative pictures
of each outcome in combination with the n number for each example. No
experimental randomization or blinding was used as this was not considered
necessary.
Transgenic zebraﬁsh. All animal procedures were approved by local ethical
review and licensed by the UK Home Ofﬁce. tg(Dll4in3:GFP) and tg(kdrl:HRAS-
mCherry) ﬁsh lines were as previously described19,32,79. The stable lines tg(Ephb4-2:
GFP) and tg(Coup-TFII-965) were generated from an initial outcross of adult F0
carriers and intercrossed with the tg(kdrl:HRAS-mCherry) to enable visualization of
the entire vasculature. F0 transient mosaic transgenic zebraﬁsh embryos were
generated using Tol2-mediated integration80. Embryos were maintained in E3
medium (5 mM NaCl; 0.17 mM KCl; 0.33 mM CaCl2; 0.33 mM MgSO4) at 28.5 °C.
To image, all embryos were dechorionated and anaesthetized with 0.1% tricaine
mesylate. For analysis of transient transgenic zebraﬁsh, single embryos were
transferred into a ﬂat bottom 96-well plate, and GFP reporter gene expression was
screened with a Zeiss LSM 710 confocal microscope at 46–50 hpf. The total number
of injected ﬁsh, ﬁsh with detectable GFP expression and ﬁsh with GFP expression
in the vasculature were noted. Whole ﬁsh were imaged using the tile scan
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command and combined with Z-stack collection under a confocal microscope Zeiss
LSM 710 MP (Carl Zeiss) at 488 nm excitation and 509 nm emission (EGFP) and
587 nm and 610 nm (mCherry), respectively. For imaging of stable zebraﬁsh
transgenic lines (in Figs. 4 and 8), zebraﬁsh embryos were treated with 0.03 mg/ml
PTU (N-phenylthiourea, P7629, Sigma) at 24 hpf to prevent melanogenesis.
Embryos were embedded in 0.4% TopVision low melting point agarose (R0801,
Thermo) in 0.14 mg/ml Tricaine (ethyl 3-aminobenzoate methanesulfonat, A5040,
Sigma) in glass bottom multi-well culture plates (MatTek).
Analysis of transgene expression was qualitative not quantitative, therefore no
statistical analysis was applied to the observations of reporter gene intensity and
pattern. Numbers of transgenic zebraﬁsh embryos used followed precedent set by
similar published papers, and was no <40/transgene. Where variations in
expression were detected within a single experimental set, this is represented in the
relevant ﬁgure by a graph summarizing variance with n numbers provided in the
legend. No experimental randomization or blinding was used as we did not
consider this necessary.
MO and chemical inhibition in zebraﬁsh. MOs were dissolved in ultrapure water
and injected into 1–2-cell stage zebraﬁsh embryos as previously described19.
Sequences are provided in Supplementary Table 1; concentrations used were:
smad1 MO 0.5 ng; smad5 MO 0.25 ng; alk1 MO; alk2 MO 3 ng; alk3a MO 5–7 ng;
alk3b MO 1.2–1.8 ng; bmpr2a MO 12 ng; bmpr2b MO 6 ng; dab2 MO 2.5 ng; tnnt2
MO 4 ng.
For pharmacological inhibition of pathways downstream of VEGF, Notch
and BMP, embryos were manually dechorionated and incubated with 100 µM
DAPM (Calbiochem) added at 10 hpf19, 40 µM LY294002 (MedChem Express)
added at 10 hpf81, 15–40 µM SL327 (SellekChem) added at 10 hpf6 or 5 µM
DMH1 (Calbiochem) added at 10 hpf18. Control embryos were treated with
identical concentrations of dimethyl sulphoxide without inhibitor.
All MO injections and use of chemical inhibitors were conducted at least three
separate times. Analysis was qualitative not quantitative, therefore no statistical
analysis was applied to the observations of staining intensity and pattern. Numbers
of zebraﬁsh embryos was no <40/tg (transgene) line. Where variations in
expression were detected within a single experimental set, this is represented in the
relevant ﬁgure by a graph summarizing variance with n numbers provided in the
legend. No experimental randomization was used as we did not consider this
necessary. Experimental blinding was not used as phenotypes of control and
treated embryos were easily detectable due to dorsalization and sprouting defects.
In situ hybridization. For zebraﬁsh whole-mount in situ hybridization, ephb4,
efnb2, alk2, alk3a and alk3b probes were generated as custom-made, double-
stranded linear DNA fragments (GeneArt® Strings™, Life Technologies), cloned
into the pCR2 vector using the TOPO/TA Cloning Kit (Invitrogen 450641) and
transcribed using SP6 and T7. The sequences are provided below. dll4, kdrl, bmp2b
and bmp4 probes were used as previously described70,72,73. Whole-mount in situ
hybridization was conducted as previously described74. Brieﬂy, embryos were
collected at 28 and 36 hpf, ﬁxed overnight at 4 °C in 4% PFA, dehydrated and
stored at −20 °C in 100% ethanol. Before use, embryos were rehydrated in 1×PBS
with 0.1% Tween-20 (PBST), bleached in 3% H2O2/0.5% KOH and then
embryos were re-ﬁxed in 4% PFA for 20 min. The embryos were made permeable
by digestion with 15 μg/ml proteinase K (Sigma-Aldrich) for 10 min (28 hpf
embryos) or 30 min (36 hpf embryos) followed by two PBST washes, ﬁxed in 4%
PFA for 20 min, washed ﬁve times with PBST, then transferred into hybridization
solution (50% formamide, 5× Saline-Sodium Citrate (SSC), 0.1% Tween 20, 50 μg/
ml heparin, 500 μg/ml yeast tRNA, 10 mM citric acid) for 2 h at 65 °C, transferred
into diluted antisense riboprobe/hybridization solution and incubated overnight at
65 °C. Probes were removed and embryos relocated to a Biolane HT1 in situ
machine (Intavis). Embryos were washed through a dilution series of 2× SSC
followed by 0.2× SSC at 65 °C and thereafter taken through room temperature
dilution washes of 100% MABT (0.1 M maleic acid, 0.15 M NaCl, pH 7.5). Non-
speciﬁc sites were blocked with MAB block (MABT with 2% Boehringer block
reagent), and the embryos were incubated for 15 h with 1:2000 antiDIG antibody
(Roche) at 4 °C, before washing in MABT. Prior to staining, embryos were washed
in alkaline phosphatase (AP) buffer and the in situ signal was developed at room
temperature with BM Purple (Sigma-Aldrich). Staining was stopped as appropriate
by ﬁxation in 4% PFA. Embryos were transferred to 80% glycerol for imaging
and storage.
All in situ analyses were conducted at least two separate times. Analysis was
qualitative not quantitative, therefore no statistical analysis was applied to the
observations of staining intensity and pattern. Numbers of zebraﬁsh
embryos were <20/in situ condition. Where variations in expression were detected
within a single experimental set, this is represented in the relevant ﬁgure by a
graph summarizing variance with n numbers provided in the legend and by the
numbers next to the representative pictures. No experimental randomization was
used as we did not consider this necessary. Experimental blinding was not used as
phenotypes of control and treated were easily detectable due to dorsalization and
sprouting defects. Sequences of each probe are provided in the Supplementary
Table 1.
For mouse in situ hybridization, Bmp4 sense and antisense RNA probes
(from Allen Brain Atlas Data Portal72) were prepared as for the zebraﬁsh.
Wild-type E9.5 and E10.5 embryos were harvested, ﬁxed overnight in 4% PFA/PBS
at 4 °C, and parafﬁn embedded as described above. Ten-µm sections were cut, de-
waxed using Histoclear and rehydrated through an ethanol series. The sections
were then digested in 20 µg/ml Proteinase K (Sigma-Aldrich) for 8 min, followed
by washes in 2 mg/ml Glycine/PBS and then PBS. Sections were ﬁxed for 20 min in
4% PFA/PBS, washed twice in PBS and then incubated in a humidiﬁed chamber for
1 h at 70 °C in Hybridization buffer (50% formamide, 5× SSC buffer pH 4.5, 50 µg/
ml yeast RNA, 1% sodium dodecyl sulphate (SDS), 50 µg/ml heparin). This was
followed by an overnight incubation in Hybridization buffer containing 1 µg/ml
sense or antisense RNA probe at 70 °C. The following morning, slides were rinsed
twice in 2× SSC buffer and then at 65 °C underwent three 15-min washes in
Solution I (50% formamide, 5× SSC pH4.5, 1% SDS) and two 15-min washes in
Solution II (50% formamide, 2× SSC pH4.5). They were then returned to room
temperature for two washes in MABT buffer (0.1 M maleic acid, 0.15 M NaCl,
0.01% Tween-20, 2 mM Levamisole (Sigma-Aldrich), pH7.5) before blocking for 1
h in 2% Boehringer Blocking Reagent (Roche)/10% sheep serum/MABT. They were
then incubated overnight at 4 °C in the blocking solution containing AP-
conjugated anti-DIG antibody (Roche) diluted 1:2000. Finally slides were washed
three times in MABT and then two times in AP buffer (100 mM Tris, pH 9.5, 50
mM MgCl2, 100 mM NaCl, 0.1% Tween-20, 2 mM Levamisol), before AP activity
was detected using BM Purple (Roche).
Immunostaining. For whole-mount DLL4 and CD31 staining, embryos were
dissected and ﬁxed in 4% PFA on ice for 1 h (DLL4) or overnight (CD31), rinsed in
PBST (0.1% TritonX-100 in PBS), incubated for 1 h in blocking solution (10%
Normal Donkey Serum in PBST), then overnight at 4 °C with goat polyclonal to
DLL4 (R&D systems, AF1389,1 in 50 dilution) or rat monoclonal to CD31 (DIA-
310, Dianova, 1 in 250 dilution). Samples were washed in PBST and subsequently
incubated overnight with suitable species-speciﬁc Alexa Fluor® or horseradish
peroxidase-conjugated secondary antibodies (1:300, Thermo Fisher Scientiﬁc) in
0.1% PBST at 4 °C.
For immunoﬂuorescence staining on parafﬁn sections, E8.5–E10.5 mouse
embryos were harvested and ﬁxed overnight in 4% PFA/PBS at 4 °C, embedded and
sectioned as described above. Sections were de-waxed by two washes in Histoclear
and rehydrated through an ethanol series. Antigen retrieval was carried out by
boiling slides in 10 mM sodium citrate buffer, pH 6.0, in a commercial pressure
cooker for 3 min, followed by two washes in PBS. Sections were then incubated at
room temperature in blocking solution (1% bovine serum albumin (BSA), 2%
donkey serum in PBS or 10% donkey serum in PBS) for 1 h in a humidiﬁed
chamber, followed by overnight incubation at 4 °C in primary antibodies diluted in
blocking solution. Sections were rinsed in PBS and incubated in species-speciﬁc
Alexa Fluor®-conjugated secondary antibodies diluted 1:1000 in blocking solution
for 1 h at room temperature. Finally, sections were rinsed further in PBS, stained
with 4,6-diamidino-2-phenylindole (DAPI) and mounted with glass coverslips
using FluoromountTM Aqueous Mounting Medium (Sigma), before imaging on a
Zeiss LSM 710 Confocal Laser Scanning Microscope. Primary antibodies used were
rat monoclonal to CD31 (DIA-310, Dianova) diluted 1:300, rabbit monoclonal to
Neuropilin 1 (ab81321, Abcam) diluted 1:100, rabbit polyclonal to ALK3 (ab38560,
Abcam) diluted 1:100 and goat polyclonal to EPHB4 (AF446, R&D Systems)
diluted 1:50.
For COUP-TFII immunohistochemical staining on parafﬁn sections, E10.5
mouse embryos were processed the same as for the immunoﬂuorescence staining
up to the antigen retrieval step. Following antigen retrieval, sections were washed in
PBS and then incubated in 3% hydrogen peroxide (Sigma Aldrich) for 5 min and
rinsed again in PBS. The Avidin/Biotin Blocking Kit (SP-2001, Vector
Laboratories) and Mouse on Mouse (M.O.M.™) Basic Kit (BMK-2202, Vector
Laboratories) were then used according to the manufacturer’s instructions, with a
mouse monoclonal antibody to COUP-TFII (PP-H7147–00, Perseus Proteomics
Inc) diluted 1:100 in the M.O.M.TM diluent. Following incubation in the M.O.M.™
Biotinylated Anti-Mouse IgG reagent, sections were incubated for 10 min in
VECTASTAIN® Elite® ABC Reagent (from PK-6102, Vector Laboratories), rinsed
in PBS and then incubated in DAB substrate (SK-4100, Vector Laboratories),
including Nickel solution, until colour developed. Slides were imaged using a
NanoZoomer S210 slide scanner with the NDP.view2 viewing software
(Hamamatsu).
For immunoﬂuorescence staining on cryosections, E9.5 mouse embryos were
harvested and ﬁxed in 4% PFA/PBS at 4 °C for 1 h, before incubation in 30%
sucrose/PBS overnight at 4 °C. They were then washed in a 50/50 mix of 30%
sucrose/OCT Embedding Medium (Thermo Scientiﬁc), two washes in OCT and
then mounted over dry ice and stored at −80 °C. Cryosections were cut at a
thickness of 12 μm, thawed at room temperature and washed in PBS to remove the
OCT embedding medium. They were ﬁxed in 4% PFA/PBS for 10 min, washed
three times in PBS and permeabilized in 0.5% Triton X-100/PBS (Merck) for 12
min. Following two further PBS washes, sections were blocked in 10% donkey
serum/0.1% Triton X-100/PBS for 1 h in a humidiﬁed chamber at room
temperature, before overnight incubation at 4 °C in primary antibodies diluted in
the blocking solution. Following further PBS washes, sections were incubated at
room temperature in Alexa Fluor®-conjugated secondary antibodies diluted 1:1000
in blocking solution for 1 h. Sections were then DAPI-stained, mounted and
imaged as described above. Primary antibodies used were rabbit monoclonal to
Phospho-SMAD1 (Ser463/465)/ SMAD5 (Ser463/465)/ SMAD9 (Ser465/467)
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(D5B10, Cell Signaling Technology), goat polyclonal to EPHB4 (AF446, R&D
Systems) diluted 1:50 and rat monoclonal to CD31 (DIA-310, Dianova)
diluted 1:300.
ClustalW and sequence motif analysis. Mouse and human sequences of putative
enhancers were aligned using ClustalW76. Binding motifs for the vascular ETS
factors ERG and ETV2 and SMAD4 were obtained from JASPAR and annotated by
hand.
Bioinformatic analysis of SMAD1/5-enriched binding sites. SMAD1/5-binding
information was obtained using publically available ChIP-seq data32 via the NCBI
GEO database77, accession number GSE27661. Raw reads for HUVEC stimulated
by BMP9 and PASMC stimulated by BMP4 sets were trimmed with Sickle. Reads
were then aligned to human genome build hg19 using Bowtie2, duplicate PCR
reads removed with rmdup and peaks were called with MACS2. A bedgraph was
generated of the signiﬁcant peaks for visualization and comparison to other
genomic data sets.
ERG-binding information from HUVEC was obtained using publically available
ChIP-seq data29 via ArrayExpress73, accession number E-MTAB-5148. Raw reads
were trimmed with Sickle, aligned to human genome build hg19 using Bowtie2,
duplicate PCR reads removed with rmdup and peaks were called with MACS2. A
bedgraph was generated of the signiﬁcant peaks for visualization and comparison
to other genomic data sets.
Chromatin immunoprecipitation. HUVECs (PromoCell, C-12203) were grown in
Endothelial Cell Growth Medium 2 with the BulletKit (PromoCell). Media was
changed every 48 h. Four 80% conﬂuent 15-cm dishes per condition were serum
starved in 0.5% Foetal Bovine Serum (Gibco) overnight before being stimulated
with BMP9 1 ng/ml for 1.5 h. Cells were then trypsinized and the cell pellet col-
lected. Crosslinking was performed in 0.6% methanol-free formaldehyde (Pierce)
under rotation at room temperature for 12’ before being quenched with glycine to a
concentration of 0.2 M. Lysis was achieved by passing cell suspension through a 25-
g needle (Terumo #NN-2525R) in 1 ml of cell lysis buffer (50 mM Tris-HCL
(pH8.0), 10 mM EDTA, 10 mM Sodium butyrate, 1% SDS, 0.5 mM phe-
nylmethanesulfonylﬂuoride and cOmplete, EDTA-free protease inhibitor cocktail
(Roche)).
To obtain a mean chromatin fragment size of 650–850 bp chromatin was
sheared by sonication using a Covaris sonicator S220 in a Covaris AFA ﬁber tube at
160W peak incidence power, 5% duty cycle, 200 cycles, for 8’. Fragment size
was checked by agarose gel. Sonicated chromatin was centrifuged at 14,000 × g, 10’,
and the supernatant was diluted in 8 ml ChIP dilution buffer (16.7 mM Tris
(pH8.0), 167 mM NaCl, 1.2 mM EDTA, 1% Triton X-100, 0.01% SDS) and
incubated overnight with 8 µg of antibody, Smad1 (Iwai North America
BMR00479) or IgG control (12–371 merckmillipore) and a no antibody control. IP
was performed with Dynabeads-protien G (ThermoFischer) and blocked overnight
in 0.5 mg/ml BSA (Sigma-Aldrich) under rotation for 1 h. G-Dynabead
immunocomplexes were washed with low-salt buffer (20 mM Tris-HCL (pH8.0)
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), high-salt buffer (20 mM
Tris-HCL (pH8.0) 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS)
and LiCl buffer (250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM
EDTA, Tris–HCL 10mM, pH 8.0). Beads were eluted in 0.2 ml elution buffer
and ChIPed-DNA was reverse crosslinked overnight at 55 °C in elution buffer
plus 0.3 M NaCL, 20 µg RNase A (Invitrogen) and 20 µg Proteinase K
(Fermentas). DNA was column puriﬁed with the QIAquick PCR Puriﬁcation
Kit (Qiagen).
Immunoprecipitated DNA was analysed by qPCR using TaqMan Custom Gene
Expression Assay Probes (ThermoFischer) designed against 100 bp regions of the
Ephb4-2 enhancer or a gene dessert region of Chromosome 7 as a negative control;
sequences are detailed in Supplementary Methods.
Each ChIP was performed on at least three biological replicates, with three
technical replicates for each. Statistical analysis was performed in the StepOne plus
software, Microsoft Excel. Input was taken as the supernatant from the non-
antibody control condition. qPCR analysis of 1% input was run alongside SMAD1
antibody analysis for each region on each qPCR. Results are expressed as the mean
of the percentage of input deﬁned as 100 × (2^(adjusted Input ct− ct IP)) across all
replicates. Signiﬁcance was calculated with a paired two-tailed t test comparing
percentage of input of control region to percentage of input of SMAD1 antibody
conditions. Graphs were produced using R statistical package.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the main data supporting the ﬁndings of this study are
available within the article, its Supplementary Figures and Methods. All ChIP-seq
datasets used in this study were previously published and are publicly available;
references and accession numbers are provided within the article. Extra data are
available from the corresponding author upon request. A reporting summary of
this article is available as a Supplementary Information ﬁle.
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